Researchers may be one step closer to creating an HIV vaccine.

This month, the Institute for Human Virology at the University of Maryland School of Medicine in Baltimore launched the first phase of clinical trials for a new treatment. The immunogen, known as the Full-Length Single Chain (FLSR), could potentially induce protective antibody responses to HIV-1 strains, going where previous trial vaccines have fallen short.

And it only took three decades and millions of deaths.